[HTML][HTML] Signal pathways of melanoma and targeted therapy

W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

[HTML][HTML] DNA methyltransferases in cancer: biology, paradox, aberrations, and targeted therapy

J Zhang, C Yang, C Wu, W Cui, L Wang - Cancers, 2020 - mdpi.com
DNA methyltransferases are an essential class of modifiers in epigenetics. In mammals,
DNMT1, DNMT3A and DNMT3B participate in DNA methylation to regulate normal …

NFE2L2 is a potential prognostic biomarker and is correlated with immune infiltration in brain lower grade glioma: a pan‐cancer analysis

Q Ju, X Li, H Zhang, S Yan, Y Li… - Oxidative Medicine and …, 2020 - Wiley Online Library
Nuclear factor, erythroid 2 like 2 (NFE2L2, NRF2) is a transcription factor that regulates
various antioxidant enzymes. It plays a vital physiological role in regulating oxidative stress …

[HTML][HTML] EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy

S Sun, F Yu, D Xu, H Zheng, M Li - … et Biophysica Acta (BBA)-Reviews on …, 2022 - Elsevier
Immune checkpoint blockade (ICB) is regarded as a promising strategy for cancer therapy.
The histone methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), has been implicated …

Attenuation of SARS‐CoV‐2 replication and associated inflammation by concomitant targeting of viral and host cap 2'‐O‐ribose methyltransferases

V Bergant, S Yamada, V Grass, Y Tsukamoto… - The EMBO …, 2022 - embopress.org
The SARS‐CoV‐2 infection cycle is a multistage process that relies on functional
interactions between the host and the pathogen. Here, we repurposed antiviral drugs …

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance

S Chen, Y Zhao, S Liu, J Zhang, YG Assaraf… - Drug Resistance …, 2022 - Elsevier
Despite the rapid advancement in the introduction of new drugs for cancer therapy, the
frequent emergence of drug resistance leads to disease progression or tumor recurrence …

[HTML][HTML] The current state of treatment and future directions in cutaneous malignant melanoma

M Ernst, A Giubellino - Biomedicines, 2022 - mdpi.com
Malignant melanoma is the leading cause of death among cutaneous malignancies. While
its incidence is increasing, the most recent cancer statistics show a small but clear decrease …

[HTML][HTML] EZH2: an accomplice of gastric cancer

W Yu, N Liu, X Song, L Chen, M Wang, G Xiao, T Li… - Cancers, 2023 - mdpi.com
Simple Summary Enhancer of zeste homolog 2 (EZH2) modifies the trimethylation of Lys-27
of histone 3, affecting downstream target genes' expression. It was reported that EZH2 is …

Epigenetic basis and targeting of cancer metastasis

R Banerjee, J Smith, MR Eccles, RJ Weeks… - Trends in Cancer, 2022 - cell.com
Despite the development of novel therapeutic approaches and improved clinical
management, survival from metastatic disease remains poor. Indeed, metastasis accounts …

[HTML][HTML] BRCA1-associated protein is a potential prognostic biomarker and is correlated with immune infiltration in liver hepatocellular carcinoma: a pan-cancer …

Q Ju, X Li, H Zhang, Y Zhao - Frontiers in Molecular Biosciences, 2020 - frontiersin.org
Background BRCA1-associated protein (BRAP) is a critical gene that regulates inflammation-
related signaling pathway and affects patients' prognosis in esophageal squamous cell …